Clinical and community trials
About this study
Intracerebral haemorrhage (ICH), bleeding into the brain, is the most serious and least treatable form of stroke, accounting for at least 10% of the 20 million new strokes that occur in the world each year.
Patients fortunate enough to survive an ICH are at very high risk of another ICH as well as heart attacks and other serious heart-related events. Whilst there is strong evidence that these risks can be reduced by good control of blood pressure (BP), many patients do not receive any BP lowering treatment or that this treatment is inadequate.
TRIDENT aims to determine the benefits of using three different BP medications (each at half the normal dose) in a single pill on preventing another stroke. This capsule with the three medications, is called the Triple Pill. The study is hoping to enrol and treat 1500 people.
Recruitment criteria
Inclusion criteria
Adults with a history of ICH stroke
Average resting BP in the 130-160 mmHg range
Clinical and community trials
About this study
People with advanced kidney disease or those receiving dialysis often have other diseases related to the heart, brain and blood vessels, known as vascular disease (for example, heart attack, stroke and poor blood circulation). However, few treatments have been proven to prevent these conditions in people with advanced kidney disease. Blood thinners (medicines that prevent blood clots) are frequently used and proven to help other groups of people who are at high risk of vascular disease.
There is little understanding of whether blood thinners provide similar benefits in people with advanced kidney disease. The aim of the TRACK study is to find out whether a low dose of blood thinning medicine can reduce heart and vascular disease better than placebo (a look alike tablet that contains no active medication) in people with advanced kidney disease.
Recruitment criteria
Inclusion:
Age ≥18 years,
Advanced kidney disease (kidney failure on dialysis, or
Global Surgery and Trauma Research
An estimated 11–32% of the global disease burden is due to surgically correctable illnesses. Lancet Commission on Global Surgery estimated that 5 billion people do not have adequate access to safe affordable surgical care when needed. Contrary to belief, investing in surgical services in low- and middle-income countries (LMICs) is affordable, saves lives, and promotes economic growth. Global Surgery is defined as an area of study, research, practice, and advocacy that seeks to improve health outcomes and achieve health equity for all people who need surgical and anaesthesia care, with a special emphasis on underserved populations and populations in crisis. Among these surgically treatable diseases, trauma causes over four million deaths annually, predominantly in LMICs and is an important aspect of Global surgery. Cancer, similarly, is the second most lethal noncommunicable disease after cardiovascular disease and accounted for about 9.9 million deaths, globally in 2020. Around 9% of all cancer death
The CEDAW Index
The United Nations (UN) treaty body system is a powerful mechanism for promoting human rights. The UN influences government action through monitoring, programs, and country-specific recommendations.
In the context of women’s rights, the Committee on the Elimination of All Forms of Discrimination Against Women (CEDAW) influences government action by periodically reviewing 189 countries every four years. Governments report on their progress ahead of each review, and civil society organisations offer grassroots perspectives to the Committee in the form of ‘shadow reports’ which validate or challenge government narratives.
The problem
A significant challenge limiting the potential of the UN treaty body system is that the CEDAW Committee lacks clarity on the implementation of its recommendations, and their overall effectiveness in achieving health and social outcomes.
Despite its 40-year history, CEDAW lacks a systematic monitoring tool to track implementation. Government
Join Us: Strengthening Australia’s research capability
Background
Australia is a world leader in health and medical research, however an ongoing research barrier is the slow recruitment of research participants across the country.
Increasing community involvement in medical research is a key goal for the government’s “National One Stop Shop” for clinical trials.
Research registers are a proven way of connecting patients and researchers, but these registers typically address specific diseases, focus on people attending metropolitan centres of excellence, and can be difficult for patients to navigate.
Disease-agnostic research registers offer participants of all types a single point of access to research.
Aims
Join Us is a not-for-profit, disease-agnostic health research register dedicated to connecting everyday Australians with meaningful research opportunities.
Join Us aims to achieve better health and wellbeing for the Australian community by removing a major barrier to the recruitment of participant
Point Prevalence Program
The Point Prevalence Program (PPP) is a collaborative project between Australian and New Zealand Intensive Care Society Clinical Trials Group (ANZICS CTG) and the Critical Care Division of The George Institute.
Aim
As a coordinated and validated project , the Point Prevalence Program provides infrastructure to conduct several multi-centre observational studies simultaneously on specified study days each year. The impetus for the PPP is to improve the efficiency of the collection of observational data that helps design clinical trial protocols for future ANZICS CTG studies. A further use of the PPP is that it can help with generating data to understand how research findings are translated into clinical practice.
Significance
The program facilitates collaborations amongst members of the CTG with an average of 44 ICUs participating each study day from a range of tertiary, metropolitan, regional-rural and private hospitals with an average recruitment per study day of more than 550 participants.
Intensive Insulin Therapy Trialists' Collaboration (IIT-TC)
Hyperglycaemia is a common finding in patients who are acutely ill even in the absence of a prior diagnosis of diabetes mellitus. In acutely ill patients, hyperglycaemia is associated with a worse outcome.
As hyperglycaemia is consistently associated with increased morbidity and mortality, critical care researchers have conducted a number of trials to investigate whether tighter control of blood glucose in critically ill patients is beneficial. To date there have been over 30 randomised controlled trials of tight glucose control in critical care settings.
However, many studies have reported non-significant results; in part this is because many of the trials were small and when considered alone had insufficient statistical power to examine the effects of tight glucose control on mortality.
Aims
The aim of this collaborative research project is to combine the individual patient data from all randomized controlled trials of tight glucose control in critically ill adults around the world to conduct
Changes in clinical guidelines for the management of chronic back pain
Policy & Practice Report
Improving the management of stroke
Policy & Practice Report
Australian Government Preventative Health Taskforce
Policy & Practice Report
Developing renal service plans
Policy & Practice Report
Assessment of absolute cardiovascular disease risk
Policy & Practice Report